CRDL Stock Chart & Stats
$2.00
>-$0.01(-0.42%)
At close: 4:00 PM EDT
$2.00
>-$0.01(-0.42%)
Day’s Range― - ―
52-Week Range$0.88 - $2.34
Previous Close$1.33
Volume288.13K
Average Volume (3M)1.54M
Market Cap
$150.67M
Enterprise Value$145.28M
Total Cash (Recent Filing)$26.08M
Total Debt (Recent Filing)$107.00K
Price to Earnings (P/E)―
Beta1.29
Next Earnings
Nov 12, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding120,660,446
10 Day Avg. Volume2,063,263
30 Day Avg. Volume1,542,615
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)6.37
Price to Sales (P/S)0.00
P/FCF Ratio-4.77
Enterprise Value/Market Cap0.96
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.26K
Enterprise Value/Ebitda-4.09
Forecast
1Y Price Target
$10.00Price Target Upside400.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.31
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Very Low LeverageMinimal debt reduces interest obligations and financial risk while preserving flexibility to fund clinical development. A lightly levered balance sheet gives Cardiol more capacity to manage operating volatility and pursue its pipeline without the constraints associated with substantial borrowings.
Losses Showed Modest ImprovementThe year-over-year reduction in net loss indicates some improvement in financial performance, even though the company remains unprofitable. If sustained, tighter loss control could slow capital consumption and support more efficient use of funding during continued clinical development.
Focused Cardiovascular Development PipelineCardiol has a defined therapeutic focus and lead programs addressing serious cardiovascular conditions, giving its development effort a coherent strategic direction. Progress through clinical trials and regulatory pathways could create future commercialization or partnering opportunities if candidates advance successfully.
Bears Say
Pre-revenue Business ModelWith no meaningful product revenue, Cardiol cannot currently fund operations through an established commercial franchise. Its financial profile therefore remains dependent on advancing unapproved candidates toward approval, leaving future value creation contingent on clinical and regulatory progress.
Persistent Cash BurnOngoing negative operating and free cash flow shows that research and operations require substantial external funding. Continued cash consumption can reduce financial flexibility over the next several quarters and may require additional capital before commercial revenues become available.
Shrinking Equity And Asset BaseThe contraction in equity and assets is consistent with repeated losses and cash use, reducing the resources available to support the development plan. Unless operating performance improves or new funding is secured, the shrinking capital base can increase dependence on future financing.
Cardiol Therapeutics News
CRDL FAQ
What was Cardiol Therapeutics’s price range in the past 12 months?
Cardiol Therapeutics lowest stock price was $0.88 and its highest was $2.34 in the past 12 months.
What is Cardiol Therapeutics’s market cap?
Cardiol Therapeutics’s market cap is $150.67M.
When is Cardiol Therapeutics’s upcoming earnings report date?
Cardiol Therapeutics’s upcoming earnings report date is Nov 12, 2026 which is in 31 days.
How were Cardiol Therapeutics’s earnings last quarter?
Cardiol Therapeutics released its earnings results on Aug 12, 2026. The company reported -$0.035 earnings per share for the quarter, beating the consensus estimate of -$0.068 by $0.033.
Is Cardiol Therapeutics overvalued?
According to Wall Street analysts Cardiol Therapeutics’s price is currently Undervalued.
Does Cardiol Therapeutics pay dividends?
Cardiol Therapeutics does not currently pay dividends.
What is Cardiol Therapeutics’s EPS estimate?
Cardiol Therapeutics’s EPS estimate is -0.06.
How many shares outstanding does Cardiol Therapeutics have?
Cardiol Therapeutics has 120,660,446 shares outstanding.
What happened to Cardiol Therapeutics’s price movement after its last earnings report?
Cardiol Therapeutics reported an EPS of -$0.035 in its last earnings report, beating expectations of -$0.068. Following the earnings report the stock price went up 12.5%.
Which hedge fund is a major shareholder of Cardiol Therapeutics?
Currently, no hedge funds are holding shares in CRDL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cardiol Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.00 (400.00% Upside)
$10.00 (400.00% Upside)
Blogger Sentiment
Neutral
CRDL Sentiment 100%
Sector Average 67%
Sector Average 67%
Crowd Wisdom
Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 0.2%
Last 30 Days ▼ 0.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
12.84%
12-Months-Change
Fundamentals
Return on Equity
-180.13%
Trailing 12-Months
Asset Growth
41.62%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Cardiol Therapeutics
Cardiol Therapeutics Inc. operates as a clinical-stage life sciences company, primarily engaged in the discovery and advancement of treatments designed to combat fibrosis and inflammation within the context of cardiovascular diseases. Its flagship product, CardiolRx, is currently undergoing a significant Phase II/III international clinical trial. This extensive study is randomized, double-blind, and placebo-controlled, evaluating CardiolRx's efficacy and safety as a heart-protective therapy to mitigate cardiovascular and respiratory issues in individuals hospitalized with COVID-19. Concurrently, the trial also assesses CardiolRx's role in addressing acute myocarditis. Beyond this, the company is developing an injectable, subcutaneous formulation of CardiolRx, intended to target cardiac scarring and inflammation that contribute to the development and worsening of heart failure. Established in 2017, Cardiol Therapeutics Inc. is based in Oakville, Canada.
CRDL Stock 12 Month Forecast
Average Price Target
$10.00
▲(400.00% Upside)
Technical Analysis
Bausch Health Companies
―
Knight Therapeutics
―
Cipher Pharmaceuticals
―
Medicure
―
Medexus Pharmaceuticals Inc
―
Ownership Overview
2.25% Insiders
0.04% Mutual Funds
20.61% Other Institutional Investors
77.01% Public Companies and
Individual Investors